IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. (Q51309912)
Jump to navigation
Jump to search
scientific article published on 19 November 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. |
scientific article published on 19 November 2016 |
Statements
1 reference
IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. (English)
1 reference
Jacobus Burggraaf
1 reference
Deepak M W Balak
1 reference
Martijn B A van Doorn
1 reference
Robert D Arbeit
1 reference
Rianne Rijneveld
1 reference
Erica Klaassen
1 reference
Tim Sullivan
1 reference
Julie Brevard
1 reference
Hok Bing Thio
1 reference
Errol P Prens
1 reference
Robert Rissmann
1 reference
19 November 2016
1 reference
174
1 reference
63-72
1 reference
Identifiers
1 reference